Ethinylestradiol with Etonogestrel (NuvaRing)
Is It Right for You?
A complete guide to Ethinylestradiol with Etonogestrel (NuvaRing) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Ethinylestradiol with Etonogestrel (NuvaRing)?
NuvaRing is a combined hormonal contraceptive vaginal ring that delivers a continuous low-dose combination of ethinylestradiol (an oestrogen) and etonogestrel (a third-generation progestogen) directly through the vaginal mucosa into the systemic circulation. Each flexible, transparent ring is worn continuously for three weeks, followed by a one-week ring-free interval, providing highly effective, once-monthly-managed contraception.
Unlike combined oral contraceptives, which are subject to first-pass hepatic metabolism and require daily administration, NuvaRing delivers a steady, low-level hormonal dose — approximately 15 micrograms of ethinylestradiol and 120 micrograms of etonogestrel per day — resulting in stable plasma concentrations and a reduced peak-dose burden. This may translate to fewer oestrogen-related side effects such as nausea for some users.
NuvaRing is a prescription-only medication in the UK. A licensed clinician must assess your medical history, cardiovascular and thrombotic risk, and relevant contraindications before it can be prescribed.
What Conditions Is NuvaRing Used For?
NuvaRing is indicated for:
highly effective prevention of pregnancy in women of reproductive age; Pearl Index of approximately 0.65 with perfect use
more predictable, lighter withdrawal bleeds compared to natural menstruation
reduction in menstrual pain associated with regular use of combined hormonal contraception
NuvaRing provides highly effective contraceptive protection but offers no barrier protection against sexually transmitted infections. Condom use remains necessary for STI prevention.
How Does NuvaRing Work?
NuvaRing exerts its contraceptive effect through three complementary mechanisms:
Ovulation suppression — ethinylestradiol and etonogestrel act at the level of the hypothalamic-pituitary-ovarian axis, suppressing the mid-cycle LH surge and thereby preventing follicular maturation and ovulation. This is the primary contraceptive mechanism.
Cervical mucus thickening — progestogenic activity from etonogestrel causes thickening of cervical mucus, creating a physical barrier hostile to sperm penetration and reducing the likelihood of fertilisation should ovulation occur.
Endometrial transformation — continuous progestogenic stimulation produces endometrial atrophy, reducing the receptivity of the uterine lining to implantation.
Etonogestrel is the biologically active metabolite of desogestrel. It has high progestogenic potency and low androgenic activity, which contributes to a favourable lipid profile and tolerability profile relative to older progestogens.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Insert the ring on day one of your menstrual cycle for immediate contraceptive protection. If started on days 2–5, additional barrier contraception is required for the first seven days.
Compress the ring and insert it into the upper vagina. Exact positioning over the cervix is not necessary; most users cannot feel the ring once correctly placed.
Remove the ring after 21 days by hooking a finger under it and pulling gently downward. Insert the new ring after the seven-day ring-free interval, regardless of whether withdrawal bleeding has fully ceased.
If the ring is accidentally expelled, rinse with cool (not hot) water and reinsert promptly. If the ring has been outside the vagina for more than three hours, additional contraception is required for seven days.
Avoid oil-based vaginal products (e.g. certain antifungal preparations) as these may degrade the ring material and reduce effectiveness.
Side Effects of NuvaRing
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Vaginal discharge, irritation, or discomfort
- Headache
- Mood changes, including low mood or irritability
- Nausea
- Breast tenderness or pain
- Decreased libido
- Breakthrough bleeding or spotting, particularly during the first one to three cycles
- Sensation of the ring during intercourse (reported by some users or partners)
- Venous thromboembolism (VTE) — deep vein thrombosis or pulmonary embolism; symptoms include unilateral leg swelling, pain, warmth, sudden breathlessness, or chest pain
- Arterial thrombosis — myocardial infarction or stroke; chest pain, sudden severe headache, facial droop, arm weakness, or speech disturbance
- Severe hypertension
- Hepatic adenoma — rare; right upper quadrant abdominal pain
- Severe allergic reaction
All combined hormonal contraceptives increase the risk of venous thromboembolism. The absolute risk remains low in healthy women but is elevated in those with additional risk factors including obesity, immobility, smoking over age 35, personal or family history of VTE, or inherited thrombophilia. NuvaRing is contraindicated in women with a history of or current VTE, known thrombophilia, or multiple major cardiovascular risk factors. The balance of risks and benefits must be individually assessed.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting NuvaRing
significantly reduce plasma levels of ethinylestradiol and etonogestrel, potentially rendering contraception ineffective. Alternative or additional contraception required.
may reduce hormonal contraceptive efficacy; specialist review required.
oestrogens may increase plasma ciclosporin levels and risk of toxicity; monitor carefully.
may modestly increase ethinylestradiol levels; not clinically significant at standard doses
Important Warnings
NuvaRing is contraindicated in women with a current or past history of VTE, known thrombophilia, or ischaemic heart disease. The combination of oestrogen and progestogen increases coagulation factor activity and reduces fibrinolysis, increasing thrombotic risk — particularly in women with pre-existing risk factors.
NuvaRing and all combined hormonal contraceptives are contraindicated in women who experience migraine with aura, due to an elevated risk of ischaemic stroke.
Blood pressure should be checked before initiating NuvaRing and monitored during use. NuvaRing is contraindicated in women with uncontrolled hypertension.
Combined hormonal contraceptives are associated with a small increased risk of breast cancer diagnosis during use and for up to ten years after cessation. Women with a current or recent history of breast cancer should not use NuvaRing.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
NuvaRing FAQs
Yes — with perfect use, NuvaRing has a Pearl Index of approximately 0.65, comparable to combined oral contraceptive pills. Its advantage lies in removing the daily adherence requirement, reducing the risk of user error.
Most users cannot feel the ring once it is correctly positioned in the upper vagina. A small number of users or partners report occasional awareness during intercourse; this is normal and does not reduce effectiveness.
If the ring has been in place for up to 28 days total, contraceptive protection is likely maintained. Beyond 28 days, additional contraception should be used and a clinician consulted.
Yes — by inserting a new ring immediately after removal without a ring-free interval, withdrawal bleeds can be delayed. This is a clinician-supported practice and is safe for most users.
No. NuvaRing provides no barrier protection against sexually transmitted infections. Condom use is required for STI prevention.